Know Cancer

or
forgot password


N/A
18 Years
N/A
Open (Enrolling)
Both
Cancer

Thank you

Trial Information


Inclusion Criteria:



- sign consent approval

- patients with metastatic disease, both of bronchogenic or non-bronchogenic origin

- 50% or more of malignant cells

Exclusion Criteria:

- patients with tumoral treatment during thoracocentesis

- 50% or less of malignant cells

Type of Study:

Observational

Study Design:

Time Perspective: Prospective

Outcome Measure:

identify specific biomarkers to more accurately characterize malignant cells in metastatic pleural disease

Outcome Description:

Research for quantitative or qualitative nuclear-matrix-proteins anomalies in secondary metastatic pleural disease and/or for anomalies in the genes coding for these proteins. Protein analysis : immunofluorenscy, western blot. Genomic analysis : CGH arrays.

Outcome Time Frame:

2 years

Safety Issue:

No

Principal Investigator

Patrice Roll

Investigator Role:

Principal Investigator

Investigator Affiliation:

Assistance Publique des Hôpitaux de Marseille

Authority:

France: Afssaps - Agence française de sécurité sanitaire des produits de santé (Saint-Denis)

Study ID:

2010-A00295-34

NCT ID:

NCT01284777

Start Date:

May 2010

Completion Date:

Related Keywords:

  • Cancer
  • cancerology
  • genetic

Name

Location